Spyre Therapeutics CFO Scott Burrows Sells Shares
CFO Scott Burrows sold 15,000 shares of Spyre Therapeutics on June 25, 2026.
Key Points
- Scott Burrows, CFO of Spyre Therapeutics, sold 15,000 shares on June 25, 2026, with the stock trading near $88.67.
- Spyre Therapeutics has a market cap of $7.7 billion, a 52-week range of $14.00 to $102.06, and a forward P/E of -28.34.
- Analysts maintain a strong buy rating with a mean price target of $100.47, highlighting continued interest in the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Scott Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc. (NasdaqGS:SYRE), sold 15,000 shares of the company. The transaction was not part of a planned sale. Shares of Spyre Therapeutics traded near $88.67 on the day of the sale.
Insider Buying and Selling at Spyre Therapeutics, Inc.
Scott Burrows, Spyre Therapeutics' CFO, sold 15,000 shares on June 25, 2026, at an average price of $87.13. This sale was not under a Rule 10b5-1 plan. Earlier on the same day, Burrows also executed a purchase of 15,000 shares at $14.50.
Other Institutional Activity in Spyre Therapeutics
Several institutional investors have been active in Spyre Therapeutics. FMR LLC increased its holdings by 142,205 shares to a total of 11,781,024 shares, valued at about $594.2 million, representing a 1.2% increase. BlackRock, Inc. slightly reduced its position by 880 shares, maintaining 5,521,221 shares worth approximately $278.5 million. Perceptive Advisors LLC notably increased its stake by 714,000 shares, a 23.3% boost, bringing its total to 3,783,225 shares valued at $190.8 million.
Spyre Therapeutics, Inc. Stock Down 2.7%
As of Saturday, shares of Spyre Therapeutics (NasdaqGS:SYRE) traded near $88.67. The company has a market cap of approximately $7.7 billion. It has a forward P/E ratio of -28.34, reflecting its current lack of profitability. The stock's beta is 3.063, indicating higher volatility compared to the broader market. Over the past 52 weeks, the stock has ranged from $14.00 to $102.06, with a 50-day moving average of $75.57 and a 200-day moving average of $42.41.
$SYRE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts remain bullish on Spyre Therapeutics, with Deutsche Bank maintaining a 'buy' rating and setting a price target of $135 on June 23, 2026. BTIG also reaffirmed its 'buy' rating with a target of $112 on June 16, 2026. The consensus among analysts is a 'strong buy,' with a mean price target of $100.47 based on 15 opinions.
About Spyre Therapeutics
Spyre Therapeutics, Inc., based in Waltham, Massachusetts, is a biotechnology company focused on developing treatments for inflammatory bowel disease and rheumatic diseases. The company is working on several clinical-stage programs, including SPY001, an antibody therapy for ulcerative colitis and Crohn's disease. Dr. Cameron Turtle leads the company as CEO, overseeing a team of 112 employees.
Bottom Line
The recent insider sale by CFO Scott Burrows is a notable development for Spyre Therapeutics, a company underpinned by strong institutional interest and robust analyst ratings. With its focus on innovative treatments for challenging diseases, Spyre continues to be a company to watch. Remember, insider transactions like these are just one piece of the puzzle, and they often occur for a variety of reasons.
Get Spyre Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SYRE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.